apixaban
E241386
Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
All labels observed (2)
How this entity was disambiguated
This entity first appeared as the object of triple T2190691 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: apixaban Context triple: [Xarelto, isComparedWith, apixaban]
-
A.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
B.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: apixaban Target entity description: Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
-
A.
Xarelto
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
B.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
E.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
- F. None of above. chosen
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant drug
ⓘ
direct oral anticoagulant ⓘ factor Xa inhibitor ⓘ small molecule ⓘ |
| approvedBy |
U.S. Food and Drug Administration
ⓘ
linked to:
Food and Drug Administration
|
| belongsToClass | oxazolidinone derivatives ⓘ |
| commonAdverseEffect |
anemia
ⓘ
bleeding ⓘ nausea ⓘ |
| contraindicatedIn |
active pathological bleeding
ⓘ
severe hypersensitivity to apixaban ⓘ |
| developedBy |
Bristol-Myers Squibb
ⓘ
linked to:
Bristol Myers Squibb
Pfizer ⓘ |
| excretedVia |
feces
ⓘ
urine ⓘ |
| hasAntidote | andexanet alfa ⓘ |
| hasApprovalYear | 2012 ⓘ |
| hasATCCode | B01AF02 ⓘ |
| hasBioavailability | approximately 50 percent ⓘ |
| hasBlackBoxWarning |
increased risk of thrombotic events after premature discontinuation
ⓘ
risk of spinal or epidural hematoma with neuraxial anesthesia or spinal puncture ⓘ |
| hasCASNumber | 503612-47-3 ⓘ |
| hasDosingFrequency | twice daily in most indications ⓘ |
| hasEliminationHalfLife | approximately 12 hours ⓘ |
| hasMechanismOfAction | selective inhibition of factor Xa ⓘ |
| hasMolecularFormula | C25H25N5O4 ⓘ |
| hasProteinBinding | approximately 87 percent ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasTradeName |
Eliquis
ⓘ
linked to:
apixaban
|
| inhibits | coagulation factor Xa ⓘ |
| interactsWith |
antiplatelet drugs
ⓘ
other anticoagulants ⓘ strong CYP3A4 inducers ⓘ strong CYP3A4 inhibitors ⓘ |
| metabolizedBy |
CYP3A4
ⓘ
CYP3A5 ⓘ |
| pregnancyCategoryUS | not assigned (formerly category B data limited) ⓘ |
| reduces |
fibrin clot formation
ⓘ
thrombin generation ⓘ |
| substrateOf |
P-glycoprotein
ⓘ
breast cancer resistance protein ⓘ
linked to:
BCRP
|
| usedFor |
prevention of recurrent deep vein thrombosis
ⓘ
prevention of recurrent pulmonary embolism ⓘ prevention of stroke in nonvalvular atrial fibrillation ⓘ prevention of systemic embolism in nonvalvular atrial fibrillation ⓘ prophylaxis of venous thromboembolism after hip replacement surgery ⓘ prophylaxis of venous thromboembolism after knee replacement surgery ⓘ treatment of deep vein thrombosis ⓘ treatment of pulmonary embolism ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: apixaban Description of subject: Apixaban is an oral anticoagulant (factor Xa inhibitor) used to prevent and treat blood clots and reduce the risk of stroke in patients with conditions such as atrial fibrillation.
Referenced by (6)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: apixaban
linked to: apixaban